The Apex Times
Above the Noise
Business Wire
BusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex Times
Back to front
Johnson & Johnson widens U.S. rollout of TECNIS PureSee intraocular lens for cataract patients
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 11, 8:08 AM EDT

Johnson & Johnson widens U.S. rollout of TECNIS PureSee intraocular lens for cataract patients

The company says its presbyopia-correcting TECNIS PureSee IOL is now more widely available for U.S. cataract surgery, aiming to give surgeons and patients another lens option designed to address age-related blurry near and intermediate vision.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Johnson & Johnson said it is expanding the U.S. availability of TECNIS PureSee IOL, a presbyopia-correcting intraocular lens (IOL) intended for use during cataract surgery. The lens is positioned as a newer option for cataract surgeons and patients seeking improved vision across multiple distances, rather than relying on glasses after surgery.

The company’s announcement, carried by Yahoo Finance, frames TECNIS PureSee IOL as an advancement in “PC-IOL” technology. PC-IOL stands for presbyopia-correcting intraocular lens, meaning the artificial lens placed in the eye to replace the eye’s natural lens can be designed to help reduce dependence on reading glasses for age-related near-vision blur.

Johnson & Johnson did not provide details in the reporting available to this update on the size of the expanded footprint, when the rollout begins for specific regions, or which clinical sites or surgeon groups will be prioritized. It also did not disclose U.S. pricing, reimbursement expectations, or any changes to launch timelines beyond the statement that availability is being increased.

Beyond the announcement itself, the information provided here does not include performance metrics, comparative trial results versus other IOLs, or any safety and adverse-event data. As a result, it is unclear from this report how TECNIS PureSee IOL compares on outcomes such as visual acuity at near and intermediate distances, reduced glare or halos, or overall patient satisfaction relative to competing extended depth of focus and similar lens designs.

The move fits a broader ophthalmology strategy in which companies seek to differentiate cataract surgery products not just by surgical materials, but by optical designs intended to broaden the range of functional vision after the procedure. For patients, the practical decision often turns on how well a chosen lens design matches lifestyle needs, such as reading, screen use, and driving in low light.

It is also notable that presbyopia-correcting IOL adoption is closely tied to surgeon familiarity and patient selection. Lenses can perform differently depending on eye anatomy and cataract characteristics, and the best-fit approach can influence outcomes. The company’s statement emphasizes availability for surgeons and patients, suggesting the rollout is aimed at widening access rather than introducing a brand-new clinical indication.

Even with an expanded rollout, the specific scope of Johnson & Johnson’s commitment remains unclear in the material available for this update. The company did not detail the number of participating sites, the expected pace of adoption across the U.S., or whether the expansion includes any training programs or updated ordering pathways.

What to watch next is whether Johnson & Johnson provides further U.S. commercialization details, such as geographic coverage, marketing or distribution milestones, and any additional clinical data or post-market insights. Over time, industry observers will also look for how the expanded availability affects demand for presbyopia-correcting lenses and how it positions TECNIS PureSee IOL against other options in the category.

Why It Matters

  • A wider rollout can increase competition in presbyopia-correcting cataract lens options, potentially shaping what surgeons can offer patients.
  • Presbyopia-correcting lenses are often chosen to reduce post-surgery dependence on glasses, which can influence patient satisfaction and satisfaction-driven referrals.
  • Expanded availability can be a announcement of manufacturing readiness and confidence in market adoption, though details were not provided here.
  • How TECNIS PureSee IOL performs in real-world use, including patient selection effects, will likely determine whether the broader access translates into meaningful share gains.
  • Patients considering cataract surgery may face more choices, while clinicians will need clear guidance on appropriate candidates and expected outcomes.

Sources

Key Facts

  • Johnson & Johnson said it is expanding U.S. availability of TECNIS PureSee IOL.
  • TECNIS PureSee IOL is described as a presbyopia-correcting intraocular lens (PC-IOL) used during cataract surgery.
  • The announcement targets both cataract surgeons and patients as the rollout broadens.
  • The company described the lens as an “advanced” option and indicated it is designed to improve vision across distances.
  • No specific U.S. rollout timeline, pricing, reimbursement information, or performance data was included in the information available for this update.

Healthcare Related

Johnson & Johnson widens U.S. rollout of TECNIS PureSee intraocular lens for cataract patients | The Apex Times